Seywright Alice, Torrance Hazel J, Wylie Fiona M, McKeown Denise A, Lowe David J, Stevenson Richard
a Department of Forensic Medicine and Science , University of Glasgow , Glasgow , UK ;
b Glasgow Royal Infirmary , Glasgow , UK ;
Clin Toxicol (Phila). 2016 Sep;54(8):632-7. doi: 10.1080/15563650.2016.1186805. Epub 2016 May 23.
MDMB-CHMICA is a synthetic cannabinoid receptor agonist which has caused concern due to its presence in cases of adverse reaction and death.
43 cases of suspected synthetic cannabinoid ingestion were identified from patients presenting at an Emergency Department and from post-mortem casework. These were subjected to liquid-liquid extraction using tertiary-butyl methyl ether and quantitatively analysed by Electrospray Ionisation Liquid Chromatography-tandem Mass Spectrometry. For positive samples, case and clinical details were sought and interrogated.
11 samples were found positive for MDMB-CHMICA. Concentrations found ranged from <1 to 22 ng/mL (mean: 6 ng/mL, median: 3 ng/mL). The age range was 15-44 years (mean: 26 years, median: 21 years), with the majority (82%) of positive results found in males. Clinical presentations included hypothermia, hypoglycaemia, syncope, recurrent vomiting, altered mental state and serotonin toxicity, with corresponding concentrations of MDMB-CHMICA as low as <1 ng/mL. Duration of hospitalisation ranged from 3 to 24 h (mean: 12 h, median: 8 h).
The concentration range presented in this case series is indicative of MDMB-CHMICA having a high potency, as is known to be the case for other synthetic cannabinoid receptor agonists. The age range and gender representation were consistent with that reported for users of other drugs of this type. The clinical presentations observed were typical of synthetic cannabinoid receptor agonists and show the difficulties in identifying reactions potentially associated with drugs of this type.
The range of MDMB-CHMICA concentrations in Emergency Department presentations (n = 9) and post-mortem cases (n = 2) was reported. No correlation between the concentration of this drug and clinical presentation or cause of death was reported in this sample. However, the potential for harm associated with low concentrations of MDMB-CHMICA and the symptoms of toxicity being non-specific were highlighted.
MDMB-CHMICA是一种合成大麻素受体激动剂,因其在不良反应和死亡病例中的出现而引发关注。
从急诊科就诊患者及尸检案例中识别出43例疑似摄入合成大麻素的病例。对这些病例采用叔丁基甲醚进行液-液萃取,并通过电喷雾电离液相色谱-串联质谱法进行定量分析。对于阳性样本,收集并询问病例及临床细节。
11份样本检测出MDMB-CHMICA呈阳性。检测到的浓度范围为<1至22纳克/毫升(平均值:6纳克/毫升,中位数:3纳克/毫升)。年龄范围为15至44岁(平均值:26岁,中位数:21岁),阳性结果的大多数(82%)出现在男性中。临床表现包括体温过低、低血糖、晕厥、反复呕吐、精神状态改变和血清素中毒,相应的MDMB-CHMICA浓度低至<1纳克/毫升。住院时间为3至24小时(平均值:12小时,中位数:8小时)。
本病例系列中呈现的浓度范围表明MDMB-CHMICA具有高效力,其他合成大麻素受体激动剂也是如此。年龄范围和性别分布与其他此类药物使用者的报告一致。观察到的临床表现是合成大麻素受体激动剂的典型表现,显示出识别可能与此类药物相关反应的困难。
报告了急诊科病例(n = 9)和尸检病例(n = 2)中MDMB-CHMICA的浓度范围。本样本中未报告该药物浓度与临床表现或死亡原因之间的相关性。然而,强调了低浓度MDMB-CHMICA相关的潜在危害以及毒性症状的非特异性。